Clinical Science Review: Update on Trimetrexate, a Folate Antagonist with Antineoplastic and Antiprotozoal Properties

References

• Baker BR. Design of Active-Site-Directed Irreversible Enzyme Inhibitors. John Wiley and Sons, New York 1967
   Google Scholar
• Elslager E F, Davoll J. Synthesis of fused pyrimidines as folate antagonists. Lectures in Heterocyclic Chemistry, RN. Castle, LB. Townsend. Hetero Corp. Orem, UT 1974; Vol. 2
   Google Scholar
• McCormack JJ. Structure-activity relationships among pteridine derivatives and related quinazolines as inhibitors of dihydrofolate reductase. Chemistry and Biology of Pteridines, W Pfleiderer, W de Gruyter, New York 1975; 125–132
   Google Scholar
• Bertino J R, Sawicki WL. Potent inhibitory activity of trimethoxyquine (TMQ), ‘nonclassical’ 2,4 diaminoquinazoline, on mammalian DNA synthesis. Proc Am Assoc Cancer Res 1977; 18: 168, abstr
   Web of Science ®Google Scholar
• Chen B K, Horvath C, Bertino JR. Multivariant analysis and quantitative structure-activity relationships: inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines. J Med Chem 1978; 22: 483–491
   Web of Science ®Google Scholar
• Bertino J R, Sawicki W L, Moroson BA, et al. 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino) methyl] quinazoline (TMQ), a potent non-classical folate antagonist inhibitor-1. Biochem Pharmacol 1979; 28: 1983–1987
   PubMed Web of Science ®Google Scholar
• Seither R L, Goldman ID. Rapid analysis of the consequences of dihydrofolate reductase (DHRF) inhibition by methotrexate (MIX) or trimetrexate (TMQ) in L1210 cells. Proc Am Assoc Cancer Res 1988; 29: 282, abstr
   Web of Science ®Google Scholar
• Matherly L H, Muench SP. Role of intracellular folate binding in tetrahydrofolate (THF) depletion in antifolate-treated L1210 cells. Proc Am Assoc Cancer Res 1988; 29: 282, abstr
   Web of Science ®Google Scholar
• NCI Clinical Brochure for trimetrexate glucuronate. Nov, 1983
   Google Scholar
• Latham B, Von Hoff D D, Elslager E. Use of a human tumor cloning system to evaluate analogs to methotrexate and mitoxantrone. Cancer Treat Rep 1984; 68: 733–738
   PubMedGoogle Scholar
• Jackson R C, Fry D W, Boritzki TJ, et al. Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Adv Enzyme Reg 1984; 22: 187–206
   PubMedGoogle Scholar
• Kamen B A, Eibl B, Cashmore AR, et al. Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[3,4,5-trimethoxyanilino) methyl]quinazoline), a non-classical antifolate in methotrexate-reistant leukemia cells in vitro. Biochem Pharmacol 1984; 33: 1697–1699
   PubMed Web of Science ®Google Scholar
• O'Dwyer P J, Shoemaker D D, Plowman J, et al. Trimetrexate: a new antifol entering clinical trials. Invest New Drugs 1985; 3: 71–75
   PubMed Web of Science ®Google Scholar
• Weir E C, Cashmore A R, Dreyer RN, et al. Pharmacology and toxicity of a potent ‘nonclassical’ 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs. Cancer Res 1982; 42: 1696–1702
   PubMed Web of Science ®Google Scholar
• Anderson J A, Andrews L K, de la Iglesia FA, et al. Single dose intravenous toxicity study of CI-898 (trimetrexate) in male and female albino mice. Warner-Lambert/Parke-Davis Research Report No. RR 745–00565. 1983
   Google Scholar
• Lin J T, Cashmore A R, Baker M, et al. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology and pharmacokinetics. Cancer Res 1987; 47: 609–616
   PubMed Web of Science ®Google Scholar
• Donehower R C, Graham M L, Thompson GE, et al. Phase I and pharmacokinetic study of trimetrexate (TMTX) in patients with advanced cancer. Proc Am Soc Clin Oncol 1985; 4: 32, abstr
   Google Scholar
• Legha S, Tenney D, Ho DH, et al. Phase I clinical and pharmacology study of trimetrexate (TMQ). Proc Am Soc Clin Oncol 1985; 4: 48, abstr
   Google Scholar
• Fanucchi M P, Walsh T D, Fleischer M, et al. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 1987; 47: 3303–3308
   PubMed Web of Science ®Google Scholar
• Stewart J A, McCormack J J, Tong W, et al. Phase I clinical and pharmacokinetic study of trimetrexate using a daily × 5 schedule. Cancer Res 1988; 48: 5029–5035
   PubMed Web of Science ®Google Scholar
• Rosen M, Ohnuma T, Zimet A, et al. Phase I study of trimetrexate (TMTX, TMQ, JB-11) glucuronate in a 5-day infusion schedule. Proc Am Assoc Cancer Res 1986; 27: 172, abstr
   Web of Science ®Google Scholar
• Jolivet J, Landry L, Pinard M-F, et al. A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol 1987; 20: 169–172
   PubMed Web of Science ®Google Scholar
• NCI Clinical Pharmacology Branch, Phase I trial of trimetrexate: Minutes of the Phase I Working Group and the Biomedical Modulators Advisory Group. July 17–18, 1985; 129–134
   Google Scholar
• Balis F M, Patel R, Luks E, et al. Pediatric phase I trial and pharmacokinetic study of trimetrexate. Cancer Res 1987; 47: 4973–4976
   PubMed Web of Science ®Google Scholar
• Sanders J, Ducore J, Kamen B, et al. A phase I trial of trimetrexate (TMTX) in children with leukemia and solid tumors. Proc Am Soc Clin Oncol 1987; 6: 44, abstr
   Google Scholar
• Lin J, Cashmore A, Baker M, et al. Trimetrexate in metastatic colorectal cancer-early phase II results in previously treated patients. Proc Am Soc Clin One 1986; 5: 96, abstr
   Google Scholar
• Leiby J, Capizzi R, Maroun J, et al. Phase 2 evaluation of the anticancer efficacy of trimetrexate. Proc 5th NCI-EORTC Symposium on New Drugs in Cancer Therapy 1986; 11: 20, abstr
   Google Scholar
• Maroun J. Clinical response to trimetrexate as sole therapy for nonsmall cell lung cancer. Semin Oncol 1988; IS: 17–21, suppl 2
   Google Scholar
• Robert F. Trimetrexate as a single agent in patients with advanced head and neck cancer. Semin Oncol 1988; 15: 22–26, suppl 2
   PubMed Web of Science ®Google Scholar
• Leiby JM. Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer. Semin Oncol 1988; 15: 27–31, suppl 2
   PubMed Web of Science ®Google Scholar
• Alberts A S, Falkson G, Badata M, et al. Trimetrexate in advanced carcinoma of the esophagus. Invest New Drugs 1988; 6: 319–321
   PubMed Web of Science ®Google Scholar
• Curley T, Engstrom C, Scher H, et al. Phase II trial of trimetrexate (TMTX) in hormone-refractory bidimensionally measurable (BDM) prostatic cancer (PC). Proc Am Soc Clin Oncol 1989; 8: 140, abstr
   Google Scholar
• Quirt I, Eisenhauer E, Knowling M, et al. Phase 2 study of trimetrexate in metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 1989; 7: 275, abstr
   Google Scholar
• Allegra C J, Chabner B A, Tuazon CU, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1987; 317: 978–985
   PubMed Web of Science ®Google Scholar
• Kovacs J A, Allegra C J, Chabner BA, et al. Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii. J Infect Dis 1987; 155: 1027–1032
   PubMed Web of Science ®Google Scholar
• Allegra C J, Kovacs J A, Drake JC, et al. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest 1987; 79: 478–482
   PubMed Web of Science ®Google Scholar
• De Lap R J, Grillo A J, Baukema J, et al. Investigator's brochure: trimetrexate glucuronate. Warner-Lambert/Parke-Davis Research Report No. RR-X-720–02211. 1985
   Google Scholar
• Hooke K E, Nelson J, Roberts BJ, et al. Cell cycle effects of trimetrexate (CI-898). Cancer Chemother Pharmacol 1986; 16: 116–120
   PubMed Web of Science ®Google Scholar
• Diddens H, Niethammer D, Jackson RC. Patterns of crossresistance to the antifolate drugs trimetrexate, metoprine, homofolate and CB 3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res 1983; 43: 5286–5292
   PubMedGoogle Scholar
• Li W W, Lin J T, Bertino JR. Basis for relative efficacy of three antifolates, methotrexate (MTX), 10-ethyl,10-deazaaminopterin (10-EDAM), and trimetrexate in a rat sarcoma model. Proc Am Assoc Cancer Res 1989; 30: 515, abstr
   Google Scholar
• Fry D W, Besserer VA. Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antfolates. Cancer Res 1988; 48: 6986–6991
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, McGuire J J, Sawicki W L, Bertino JR. Effects of methotrexate and of the ‘neoclassical’ folate antagonist trimetrexate on human leukemia cells. Leukemia 1987; 1: 116–120
   PubMed Web of Science ®Google Scholar
• Theiss J C, Krishna G, Kropko M-L, et al. Effect of leucovorin (LCV) on the in vitro cytotoxic and clastogenic activity of trimetrexate (TMTX). Proc Am Assoc Cancer Res 1989; 30: 472, abstr
   Google Scholar
• Bertino J R, Mini E, Sobrero A, et al. Methotrexate resistant cells as targets for selective chemotherapy. Adv Enzyme Reg 1986; 24: 3–11
   Google Scholar
• Mini E, Sobrero A, Moroson BA, et al. Differential efficacy of trimetrexate (2,4-diamino-6-methyl-((3,4,5-trimethoxyanilino) methyl)quinazalone, JB-11, TMQ) and methotrexate (MTX) on human colon carcinoma and human leukemia cells in vitro. Proc Am Assoc Cancer Res 1985; 26: 230, abstr
   Web of Science ®Google Scholar
• Sirotnak F M, Moccio D M, Kelleher LE, et al. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate resistant L1210 clonal cell lines derived in vivo. Cancer Res 1981; 41: 4447–4452
   PubMed Web of Science ®Google Scholar
• Mini E, Moroson B A, Franco CT, et al. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines. Cancer Res 1985; 45: 325–330
   PubMed Web of Science ®Google Scholar
• Cowan K H, Jolivet JJ. A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. J Biol Chem 1984; 257: 10793–10800
   Google Scholar
• Frei E, III, Rosowsky A, Wright JE, et al. Development of methotrexate resistance in a human squamous cell carcinoma of the head and neck in culture. Proc Natl Acad Sci (USA) 1984; 81: 2873–2877
   PubMed Web of Science ®Google Scholar
• Ohnoshi T, Ohnuma T, Takahashi I, et al. Establishment of methotrexate resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists. Cancer Res 1982; 42: 1655–1660
   PubMed Web of Science ®Google Scholar
• Pizzorno G, Mini E, Coronello M, et al. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res 1988; 48: 2149–2155
   PubMed Web of Science ®Google Scholar
• Simonsen C C, Levinson AD. Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci (USA) 1983; 80: 2495–2499
   PubMed Web of Science ®Google Scholar
• Bertino J R, Srimatkandada S, Carman MD, . Mechanisms of methotrexate resistance in acute leukemia. Normal and Neoplastic Hematopoiesis, DW Golde, PA Marks, et al. Alan R. Liss Inc., New York, 465–478
   Google Scholar
• Dedhar S, Hartley D, Goldie JH. Increased dihydrofolate reductase activity in methotrexate-resistant human promyelocytic-leukaemia (HL-60) cells. Biochem J 1985; 225: 609–617
   PubMed Web of Science ®Google Scholar
• Kano Y, Ohnuma T, Holland JF. Folate requirements of methotrexate resistant human acute lymphoblastic leukemia cell lines. Blood 1986; 68: 586–591
   PubMed Web of Science ®Google Scholar
• Biedler J L, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells hi vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970; 30: 1174–1184
   PubMed Web of Science ®Google Scholar
• Juliano R, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 1976; 455: 152–162
   PubMed Web of Science ®Google Scholar
• Inaba M, Kobayashi H, Sakurai Y, et al. Active efflux of daunomycin and adriamycin in sensitive and resistant sublines in P388 leukemia. Cancer Res 1979; 39: 2200–2203
   PubMed Web of Science ®Google Scholar
• Klohs W D, Steinkampf R W, Besserer JA, et al. Cross resistance of pleiotropically drug resistant P388 leukemia cells to the lipophilic antifolates trimetrexate and BW 310U. Cancer Lett 1986; 31: 253–260
   PubMed Web of Science ®Google Scholar
• Arkin H, Ohnuma T, Holland JF, et al. Multi-drug (pleiotropic) resistance in trimetrexate (TMQ)-resistant human acute lymphoblastic leukemia (ALL) cell line, MOLT-3. Proc Am Assoc Cancer Res 1986; 27: 269, abstr
   Web of Science ®Google Scholar
• Ramu N, Ramu A, Pollard HB, et al. Resistance to trimetrexate (TMQ) is related to pleiotropic drug resistance. Proc Am Assoc Cancer Res 1986; 27: 391, abstr
   Web of Science ®Google Scholar
• Klohs W D, Steinkampf R W, Leopold W R, Fry DW. Potentiation of adriamycin, trimetrexate and an AMSA analog (CI 921) cytotoxicities by amiodarone and reserpine in multidrug resistant P388 cells. Proc Am Assoc Cancer Res 1987; 28: 298, abstr
   Web of Science ®Google Scholar
• Arkin H, Ohnuma T, Yee ES, et al. Studies of membrane glycoprotein in trimetrexate (TMQ)-resistant human leukemic cells. Proc Am Assoc Cancer Res 1987; 28: 297, abstr
   Web of Science ®Google Scholar
• Klohs W, Steinkampf R, McMichael A, et al. Development of resistance to the anthrapyrazole CI-937 in L1210 cells. Proc Am Assoc Cancer Res 1989; 30: 523, abstr
   Google Scholar
• Assaraf Y G, Molina A, Schimke RT. Amplification of MDR 1 and/or DHFR genes in hamster cells resistant to the lipophilic antifolates trimetrexate and piritrexim. Proc Am Assoc Cancer Res 1989; 30: 477, abstr
   Google Scholar
• Assaraf Y G, Molina A, Schimke RT. Cross-resistance to the lipidsoluble antifolate trimetrexate in human carcinoma cells with the multidrug resistant phenotype. J Natl Cancer Inst 1989; 81: 290–294
   PubMed Web of Science ®Google Scholar
• Ramu N, Ramu A, Cole DE, et al. Mechanism of acquired resistance to methotrexate in P388 marine leukemia cells and in their doxorubicin-resistant subline. Isr J Med Sci 1988; 24: 477–482
   PubMedGoogle Scholar
• Takemura Y, Ohnuma T, Yee ES, et al. A human leukemic cell line resistant to two new folate analogues, trimetrexate (TMQ) and N10-propargyl-5,8-dideazafolic acid (CB3717). Proc Am Assoc Cancer Res 1987; 28: 276, abstr
   Web of Science ®Google Scholar
• Hamada H, Tsuruo T. Purification of the 170-to-180-kilodalton membrane glycoprotein associated with multidrug resistance. J Biol Chem 1988; 263: 1454–1458
   PubMed Web of Science ®Google Scholar
• Shen D W, Fojo A, Roninson IB, et al. Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 gene. Mol Cell Biol 1986; 6: 4039–4044
   PubMed Web of Science ®Google Scholar
• Akiyama J I, Cornwell M M, Kuwano M, et al. Most drugs that reverse multidrug resistance also inhibit photoaffinity labelling of P-glycoprotein by a vinblastine analog. Mol Pharmacol 1988; 33: 144–147
   PubMed Web of Science ®Google Scholar
• Lincke C R, van der Bliek A M, van der Velde-Koerts T, et al. Phenotype of the wild-type human mdr1 gene. Proc Am Assoc Cancer Res 1989; 30: 519, abstr
   Google Scholar
• Scheithauer W, Moyer M P, Clark G M, von Hoff DD. Application of a new preclinical drug screening system for cancer of the large bowel. Cancer Chemother Pharmacol 1988; 21: 31–34
   PubMed Web of Science ®Google Scholar
• Minton M P, Atkinson T, Sherwood RF. Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol 1987; 156: 1222–1227
   Google Scholar
• Romanini A, Chou T C, Bertino JR. Carboxypeptidase G2 enhances trimetrexate cytotoxicity in CCRF-CEM lines sensitive and resistant to methotrexate. Adv Enzyme Regul 1989; 27: 28–33
   Google Scholar
• Romanini A, Sobrero A F, Chou TC, et al. Folate depletion induced by carboxypeptidase G2 enhances trimetrexate cytotoxicity in vitro and in vivo. Cancer Res 1989; 49: 6019–6023
   PubMedGoogle Scholar
• Kalghatgi K K, Moroson B A, Horvath C, Bertino JR. Enhancement of antitumor activity of 2,4-diamino-5-(3′,4′-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (Triazinate) with carboxypeptidase G1. Cancer Res 1979; 39: 3441–3445
   PubMed Web of Science ®Google Scholar
• Leopold W R, Dykes D D, Griswold DP, Jr. Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, cytoxan, 6-thioguanine, 5-fluorouracil vincristine or cisplatin against P388 leukemia. Proc Am Assoc Cancer Res 1986; 27: 253, abstr
   Web of Science ®Google Scholar
• Fry DW. Cytotoxic synergism between trimetrexate and etoposide in L1210 cells: trimetrexate-mediated potentiation of the proteinassociated DNA strand breaks produced by etoposide. Proc Am Assoc Cancer Res 1988; 29: 483, abstr
   Web of Science ®Google Scholar
• Sobrero A, Romanini A, Russello O, et al. Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction. Eur J Cancer Clin Oncol 1989; 25: 977–982
   PubMedGoogle Scholar
• Howard C T, Hook K E, Leopold WR. Sequence and schedule dependent synergy of trimetrexate in combination with 5-fluorouracil or cisplatin. Proc Am Assoc Cancer Res 1987; 28: 417, abstr
   Web of Science ®Google Scholar
• Mini E, Mazzei T, Coronello M, Periti P. Comparative effects of two non-classical antifolates, trimetrexate (TMQ) and triazinate (TZT) on 5-fluorouracil (FURA) cytotoxicity against human CCRF-CEM leukemia cells. Proc Am Assoc Cancer Res 1989; 24: 475, abstr
   Google Scholar
• Sobrero A, Romanini A, Russello O, et al. Trimetrexate-fluoropyrimidines vs methotrexate-fluoropyrimidines: implications of their identical sequence dependent interactions in vitro. Eur J Cancer, in press
   Google Scholar
• Galivan J, Nimec Z, Rhee M. Synergistic growth inhibition of hepatoma cells exposed in vitro, to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine. Cancer Res 1987; 47: 5256–5260
   PubMed Web of Science ®Google Scholar
• Galvan J, Nimec Z, Rhee M, et al. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate. Cancer Res 1988; 48: 2421–2425
   PubMed Web of Science ®Google Scholar
• Galivan J, Rhee M S, Johnson TB, et al. The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase. J Biol Chem 1989; 264: 10685–10692
   PubMed Web of Science ®Google Scholar
• Thorndike J, Gaumont Y, Powers J, et al. Synergistic growth inhibition of human lymphoma cells by combination of trimetrexate with 5,10-dideazatetrahydrofolate. Proc Am Assoc Cancer Res 1988; 29: 285, abstr
   Web of Science ®Google Scholar
• Gaumont Y, Kisliuk R, Emkey R, et al. Folate enhancement of antifolate synergism in human leukemia cells. Proc Am Assoc Cancer Res 1989; 30: 474, abstr
   Google Scholar
• Allegra C J, Kovacs J A, Drake JC, et al. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med 1987; 165: 926–931
   PubMed Web of Science ®Google Scholar
• Kovacs J A, Allegra C J, Kennedy S, et al. Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of a rodent Pneumocystis carinii pneumonia. Am J Trop Med Hyg 1988; 39: 491–496
   PubMed Web of Science ®Google Scholar
• McCormack J J, Heusner J J, Hacker MP, et al. Further pharmacological studies of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino) methyl] quinazoline (NSC 249007;TMQ). Proc Am Assoc Cancer Res 1981; 22: 245, abstr
   Web of Science ®Google Scholar
• Heusner J J, Tong W P, McCormack JJ, et al. Disposition of the non-classical folate antagonist 2,4-diamino-5-methyl-6-(3,4,5-trimethoxyanilino) methyl quinazoline (TMQ; trimetrexate) in mice. Proc Am Assoc Cancer Res 1985; 26: 234, abstr
   Web of Science ®Google Scholar
• Andrews L, McGhee C, Anderson J, et al. Preclinical toxicological evaluation of the chemotherapeutic agent trimetrexate. Proc Am Assoc Cancer Res 1985; 26: 370, abstr
   Web of Science ®Google Scholar
• Gans J H, Tong W P, Whitfield LR, et al. Pharmacokinetic studies with trimetrexate in dogs. Proc Am Assoc Cancer Res 1986; 27: 405, abstr
   Web of Science ®Google Scholar
• Marsh JC. Comparative effects of methotrexate, two nonclassic folic acid antagonists, and cytarabine on hematopoietic precursor cells. Cancer Treat Rep 1982; 66: 499–504
   PubMedGoogle Scholar
• Bogliolog V G, Lerza R A, Manlio PM, et al. Toxicity of trimetrexate on hemopoietic progenitor cells in normal mice. Anticancer Res 1988; 8: 229–232
   PubMed Web of Science ®Google Scholar
• Rosenthal G J, Germolec D R, Lam KR, et al. Comparative effects on the immune system of methotrexate and trimetrexate. Int J Immunopharmacol 1987; 9: 793–801
   PubMed Web of Science ®Google Scholar
• Rosenthal G J, Weigand G W, Germolec DR, et al. Suppression of B cell function by methotrexate and trimetrexate. Evidence for inhibition of purine biosynthesis as a major mechanism of action. J Immunol 1988; 141: 410–416
   PubMed Web of Science ®Google Scholar
• Duch D S, Edelstein M P, Nichol CA. Inhibition of histamine-metabolizing enzymes and elevation of histamine levels in tissues by lipid-soluble anticancer folate antagonists. Mol Pharmacol 1980; 18: 100–104
   PubMed Web of Science ®Google Scholar
• Gans J H, Tong W P, Whitfield LR, et al. Dose proportionality study of trimetrexate oral absorption in dogs. Proc Am Assoc Cancer Res 1987; 28: 433, abstr
   Web of Science ®Google Scholar
• Tong W P, Gans J R, Whitfield LR, et al. Relative bioavailability study of trimetrexate in dogs. Proc Am Assoc Cancer Res 1988; 29: 505, abstr
   Web of Science ®Google Scholar
• Wong B, Whitfield L, Change T, Woolf T. Identification of major metabolites of trimetrexate in urine and bile of rat. Proc Am Assoc Cancer Res 1989; 30: 537, abstr
   Google Scholar
• Whitfield L, Chang T, Wong B. Distribution of 14C-trimetrexate in tissues of male and female rats. Proc Am Assoc Cancer Res 1989; 30: 533, abstr
   Google Scholar
• Webster L K, Tong W P, McCormack JJ. Metabolism and biliary excretion of trimetrexate by the isolated perfused rat liver. Cancer Lett 1987; 29: 65–71, abstr
   Web of Science ®Google Scholar
• Tong W P, Mathews L A, McCormack JJ. Disposition of trimetrexate (TMTX) in the isolated perfused mouse liver. Proc Am Assoc Cancer Res 1987; 28: 435, abstr
   Web of Science ®Google Scholar
• Balis F M, Lester C M, Poplack DG. Pharmacokinetics of trimetrexate (NSC 352122) in monkeys. Cancer Res 1986; 46: 169–174
   PubMed Web of Science ®Google Scholar
• Hudes G R, La Creta F, Delap RJ, et al. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. Cancer Chemother Pharmacol 1989; 24: 117–122
   PubMed Web of Science ®Google Scholar
• Stetson P L, Shukla U A, Ensminger WD. Stability of trimetrexate, a new non-classical antifolate, in infusion solutions. J Chromatogr 1989; 464: 163–171
   PubMed Web of Science ®Google Scholar
• Donehower R C, Grochow L B, Ettinger ES. Phase I study of trimetrexate. Minutes Phase I Working Group and Biochem Modulators Advisory Group. Washington, DC July 17–18, 1985; 101–106
   Google Scholar
• Reece P A, Morris R G, Bishop JF, et al. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer. Cancer Res 1987; 47: 2996–2999
   PubMed Web of Science ®Google Scholar
• Bishop J F, Raghavan D, Olver IN, et al. A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion. Cancer Chemother pharmacol 1989; 24: 246–250
   PubMed Web of Science ®Google Scholar
• Grochow L B, Noe D A, Dole GB, et al. Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics. J Natl Cancer Inst 1989; 81: 124–130
   PubMed Web of Science ®Google Scholar
• Hudes G R, Comis RL. Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer. Semin Oncol 1988; 15: 41–45, suppl 2
   PubMed Web of Science ®Google Scholar
• Maroun JA, Natale R B, Robert F. Trimetrexate combined with cisplatin or etoposide in the treatment of nonsmall cell lung cancer: a pilot study. Semin Oncol 1988; 15: 38–40, suppl 2
   PubMed Web of Science ®Google Scholar
• Hudes G, La Creta F, Walczak J, et al. Phase I pharmacologic study of trimetrexate (TMTX) and cisplatin (DDP) in combination. Proc Am Assoc Cancer Res 1989; 30: 246
   Google Scholar
• Stewart JA. Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients refractory to conventional therapy or for which no conventional therapy exists. Semin Oncol 1988; 15: 10–16, suppl 2
   PubMed Web of Science ®Google Scholar
• Ho D HW, Covington W P, Legha SS, et al. Clinical pharmacology of trimetrexate. Clin Pharmacol Ther 1987; 42: 351–356
   PubMed Web of Science ®Google Scholar
• Grem J L, Ellenberg S S, King S A, Shoemaker DD. Correlates of severe or life-threatening toxic effects from trimetrexate. J Natl Cancer Inst 1988; 80: 1313–1318
   PubMed Web of Science ®Google Scholar
• Eisenhauer E A, Zee B C, Pater J L, Walsh WR. Trimetrexate predictors of severe or life-threatening toxic effects. J Natl Cancer Inst 1988; 80: 1318–1322
   PubMed Web of Science ®Google Scholar
• Weiss R B, James W D, Major WB, et al. Skin reactions induced by trimetrexate, an analog of methotrexate. Invest New Drugs 1986; 4: 159–163
   PubMed Web of Science ®Google Scholar
• Chawla SP, Kavanagh J J, Freedman RS, et al. Pulmonary toxicity and limited activity of trimetrexate in recurrent carcinoma of the uterine cervix. Proc Am Assoc Cancer Res 1988; 29: 207, abstr
   Web of Science ®Google Scholar
• King S A, Grem JL. Acute allergic reactions to trimetrexate. Proc Am Soc Clin Oncol 1988; 7: 7, abstr
   Google Scholar
• Ackerly C A, Hartshorn J, Tong WP, et al. A rapid and sensitive method for determination of trimetrexate from biological fluids. J Liq Chromatog 1985; 8: 125–134
   Web of Science ®Google Scholar
• Rogers P, Allegra C J, Murphy RP, et al. Bioavailability of oral trimetrexate in patients with acquired immune deficiency syndrome. Antimicrob Agents Chemother 1988; 32: 324–326
   PubMed Web of Science ®Google Scholar
• Tong W P, Stewart J A, McCormack JJ, et al. Metabolism of 2,4-diamino-5-methyl-6-(3,4,5-trimethoxyanilino) methylquinazoline (trimetrexate, TMQ) in man. Proc Am Soc Clin Oncol 1985; 4: 31, abstr
   Google Scholar
• McCormack J J, Webster L K, Tong WP, et al. Studies of a metabolite of trimetrexate. Proc Am Assoc Cancer Res 1986; 27: 256, abstr
   Web of Science ®Google Scholar
• Kris M G, D'Acquisto R W, Gralla RJ, et al. Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer. Am J Clin Oncol 1989; 12: 24–24
   PubMed Web of Science ®Google Scholar
• Costanza M E, Korzon A H, Rice M A, Wood WC. A phase II study of trimetrexate in previously untreated metastatic breast cancer patients. Proc Am Soc Clin Oncol 1988; 7: 30, abstr
   Google Scholar
• Ajani J, Abbrezzese J, Blackburn R, et al. Phase II evaluation of trimetrexate (TMTX) in patients with advanced colorectal carcinoma (CRC). Proc Am Soc Clin Oncol 1988; 7: 115, abstr
   Google Scholar
• Sternberg C N, Yagoda A, Scher H, et al. Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Eur J Cancer Clin Oncol 1989; 25: 753–754
   PubMedGoogle Scholar
• Doroshow J, Odujinrin O, Flam M, et al. Trimetrexate in locally advanced or metastatic adenocarcioma of the pancreas: a phase I study of the Northern California Oncology Group. Proc Am Soc Clin Oncol 1989; 8: 111, abstr
   Google Scholar
• Brown T, Fleming T, MacDonald J. A randomized trial of two schedules of trimetrexate (TMTX) versus 5-fluorouracil (5FU) in colorectal carcinoma: a Southwest Oncology Group study. Proc Am Soc Clin Oncol 1988; 7: 109, abstr
   Google Scholar
• Young FE. The role of the FDA in the effort against AIDS. Public Health Rep 1988; 13: 242–245
   Google Scholar
• Green J A, Dawson A A, Fell LF. Measurement of drug dose intensity in MVPP therapy in Hodgkin's disease. Br J Clin Pharmacol 1980; 9: 511–514
   PubMed Web of Science ®Google Scholar
• Hryniuk W, Bush H. The importance of dose intensity in the chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–1288
   PubMed Web of Science ®Google Scholar